Pharmaceutical compositions comprising meloxicam
AssigneeAxsome Therapeutics, Inc.
InventorHerriot Tabuteau
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.
Claims26
A method of dissolving a combination of meloxicam and a rizatriptan in a stomach of a human being, comprising orally administering, to the human being, a solid dosage form comprising:
- 1) meloxicam, 2) a sulfobutyl ether β-cyclodextrin (SBEβCD), 3) a bicarbonate, and 4) the rizatriptan, wherein the solid dosage form has improved dissolution of meloxicam as compared to a reference solid dosage form containing:
- 1) the same amount of meloxicam, 2) the same amount of the SBEβCD, and 3) no bicarbonate, wherein the improved dissolution of meloxicam is determined by the following test:
- adding the solid dosage form or the reference solid dosage form to 500 mL of a 0.01 N HCl aqueous solution, stirring at 75 revolutions per minute (RPM) with a USP paddle apparatus II at 37° C., and determining the amount of meloxicam dissolved in the 0.01 N HCl aqueous solution after 15 minutes.
A method of dissolving a combination of meloxicam and a rizatriptan in a stomach of a human being, comprising orally administering, to the human being, a solid dosage form comprising:
- 1) meloxicam, 2) a sulfobutyl ether β-cyclodextrin (SBEβCD), 3) a bicarbonate, and 4) the rizatriptan, wherein the solid dosage form has improved dissolution of meloxicam as compared to a solid reference dosage form containing:
- 1) the same amount of meloxicam, 2) the same amount of the SBEβCD, and 3) no bicarbonate, wherein the improved dissolution of meloxicam is determined by the following test:
- adding the solid dosage form or the reference solid dosage form to 500 mL of a 0.01 N HCl aqueous solution, stirring at 75 revolutions per minute (RPM) with a USP paddle apparatus II at 37° C., and determining the amount of meloxicam dissolved in the 0.01 N HCl aqueous solution after 60 minutes.
Dependencies are inferred from the claim text.